FDA Grants Adjuvant Dabrafenib/Trametinib Breakthrough Designation for BRAF+ Melanoma

October 23, 2017 – The FDA has awarded the combination of dabrafenib and trametinib a breakthrough therapy designation for the adjuvant treatment of patients with stage III melanoma with a BRAF V600 mutation following complete resection. If approved, the combination would be the first adjuvant treatment specifically aimed at this patient population, Novartis, the manufacturer of the regimen, reported in a press release. “There is a need for more effective treatment … (leggi tutto)